Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

GoodRx Holdings, Inc.

GDRX Nasdaq Services-Computer Processing & Data Preparation Financials FY2018–FY2025

Last close · Oct 23, 2026

$3.54

2.2%
Compare
Revenue Total sales reported in the income statement.
$797M
0.6% vs prior year
Operating margin Operating income as a share of revenue.
11.0%
2.7 pts
Net income Profit after all expenses, interest and tax.
$30.4M
85.7%
Free cash flow Cash from operations minus capital spending.
$164M
10.0%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
6.7%
1.2 pts
Market cap Last close times the latest diluted share count, so it is approximate.
$1.2B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
88.5x
On $0.04 EPS (TTM)

What GoodRx Holdings, Inc. does

No business description yet.

Legal name
GoodRx Holdings, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K · Feb 26, 2026
Accession · CIK
0001809519-26-000031
0001809519

Revenue and margins

GoodRx Holdings, Inc. had $797M of revenue in fiscal 2025, up 0.6% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

From fiscal 2018 to 2025, diluted EPS grew −4.0% a year. Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $164M in fiscal 2025, 20.6% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

GoodRx Holdings, Inc. returned $216M to shareholders in fiscal 2025, 132% of free cash flow. The diluted share count fell 9.0%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably GoodRx Holdings, Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $941M$757M$672M$448M$262M
Debt incl. finance leases $674M$667M$656M$500M$495M
Net debt / EBITDA −5.6x−1.6x−0.2x0.4x1.4x
Debt / equity 0.8x0.8x0.9x0.7x0.8x
Interest coverage 0.6x0.1x−0.5x1.2x2.1x
Current ratio 13.4x12.1x7.1x5.3x2.6x
Quick ratio 13.4x12.1x7.1x5.3x2.6x
Total assets $1.6B$1.6B$1.6B$1.4B$1.4B
Total liabilities $776M$790M$827M$663M$788M
Shareholders' equity $832M$815M$762M$725M$616M
Net debt (− = net cash) −$267M−$90.1M−$15.8M$51.7M$233M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive ✓ ✓ ✕ ✕ ✕ ✕ ✓ ✓
Cash from operations is positive ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Return on assets rose — — ✕ ✓ ✕ ✓ ✓ ✓
Cash from operations exceeds net income ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Debt fell relative to assets — — ✓ ✓ ✓ ✓ ✓ ✓
Current ratio rose — — ✓ ✕ ✕ ✕ ✕ ✕
Share count didn't rise — ✕ ✕ ✕ ✕ ✓ ✓ ✓
Gross margin rose — — — — — — — —
Revenue rose relative to assets — — ✕ ✓ ✓ ✕ ✓ ✕
F-score — / 3— / 44 / 85 / 84 / 85 / 87 / 86 / 8
Accruals ratio —−4.5%−45.8%−13.3%−11.2%−9.2%−11.3%−9.8%
Altman Z'' —−7.461.222.421.600.960.61−0.18

8 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

Download CSV
Fiscal yearFY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $250M $388M $551M $745M $767M $750M $792M $797M
Research and development $43.9M $29.3M $61.8M $126M $143M $136M $124M $121M
Operating income $77.3M $140M −$276M $13.4M $1.7M −$27.0M $65.8M $87.5M
Interest expense $22.2M $49.6M $27.9M $23.6M $34.2M $56.7M $52.9M $42.6M
Pretax income $52.3M $83.0M −$303M −$10.2M −$23.2M −$55.6M $31.5M $56.5M
Income tax $8.6M $16.9M −$9.8M $15.1M $9.6M −$46.7M $15.1M $26.1M
Net income $43.8M $66.0M −$294M −$25.3M −$32.8M −$8.9M $16.4M $30.4M
Net income to common $13.8M $42.4M −$294M −$25.3M — — — —
Diluted EPS $0.12 $0.18 −$1.07 −$0.06 −$0.08 −$0.02 $0.04 $0.09
Diluted shares 0.12B 0.23B 0.27B 0.41B 0.41B 0.41B 0.39B 0.36B
Cash flow
Cash from operations $45.3M $83.3M $131M $179M $147M $138M $184M $168M
Capital expenditure $0.8M $1.4M $20.6M $4.6M $4.0M $1.0M $1.2M $3.5M
Free cash flow $44.4M $81.9M $111M $174M $143M $137M $183M $164M
Depreciation and amortization $9.8M $13.6M $18.4M $34.5M $54.2M $108M $69.5M $85.2M
Stock-based compensation $1.8M $3.7M $397M $160M $120M $105M $99.0M $76.6M
Acquisitions — $31.3M $55.8M $140M $157M $0.0M $0.0M $43.4M
Share buybacks — — $0.0M $0.0M $102M $104M $159M $216M
Dividends paid $1.3B — — — — — — —
Dividends and buybacks $1.3B — $0.0M $0.0M $102M $104M $159M $216M
Balance sheet
Cash and short-term investments $34.6M $26.1M $969M $941M $757M $672M $448M $262M
Total debt — $671M $681M $674M $667M $656M $500M $495M
Current assets — $86.6M $1.1B $1.1B $920M $873M $659M $643M
Current liabilities — $33.4M $59.6M $81.1M $76.3M $123M $124M $246M
Property and equipment, net — $1.9M $23.1M $21.6M $19.8M $15.9M $12.7M $12.3M
Goodwill $220M $236M $261M $330M $412M $411M $411M $430M
Intangible assets — $21.3M $36.9M $88.8M $120M $60.9M $52.1M $64.1M
Total assets — $387M $1.5B $1.6B $1.6B $1.6B $1.4B $1.4B
Total liabilities — $737M $759M $776M $790M $827M $663M $788M
Preferred stock — — $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Shareholders' equity −$1.2B −$1.1B $711M $832M $815M $762M $725M $616M
Margins
Operating margin 31.0% 36.0% −50.1% 1.8% 0.2% −3.6% 8.3% 11.0%
EBITDA margin 34.9% 39.5% −46.7% 6.4% 7.3% 10.8% 17.1% 21.7%
Net margin 17.6% 17.0% −53.3% −3.4% −4.3% −1.2% 2.1% 3.8%
FCF margin 17.8% 21.1% 20.1% 23.4% 18.6% 18.3% 23.1% 20.6%
Returns
Return on capital — — −51.4% 1.9% 0.2% −2.9% 5.5% 6.7%
Return on capital employed — 39.5% −19.5% 0.9% 0.1% −1.8% 5.2% 7.6%
Return on equity — — — −3.3% −4.0% −1.1% 2.2% 4.5%
Return on assets — 17.1% −31.6% −1.6% −2.0% −0.6% 1.1% 2.2%
Return on tangible equity — — −71.0% −6.1% −11.6% −3.1% 6.3% 25.0%
Growth
Revenue growth — 55.6% 41.9% 35.4% 2.8% −2.1% 5.6% 0.6%
Net income growth — 50.8% −544.6% — — — — 85.7%
EPS growth — 50.0% −694.4% — — — — 125.0%
FCF growth — 84.2% 35.3% 57.2% −18.0% −3.9% 33.1% −10.0%
Share count change — 95.4% 18.8% 49.2% 0.7% −0.6% −4.4% −9.0%
Financial health
Net debt / EBITDA — 4.2x — −5.6x −1.6x −0.2x 0.4x 1.4x
Debt / equity — — 1.0x 0.8x 0.8x 0.9x 0.7x 0.8x
Interest coverage 3.5x 2.8x −9.9x 0.6x 0.1x −0.5x 1.2x 2.1x
Current ratio — 2.6x 18.2x 13.4x 12.1x 7.1x 5.3x 2.6x
Quick ratio — 2.6x 18.2x 13.4x 12.1x 7.1x 5.3x 2.6x
Capital allocation
Capex / revenue 0.3% 0.4% 3.7% 0.6% 0.5% 0.1% 0.2% 0.4%
Stock comp / revenue 0.7% 1.0% 72.1% 21.5% 15.7% 14.0% 12.5% 9.6%
Payouts / FCF 3,029.0% — 0.0% 0.0% 71.2% 75.8% 87.0% 131.6%
Quality scores
Piotroski F-score — — 4.0 5.0 4.0 5.0 7.0 6.0
Altman Z'' — −7.5 1.2 2.4 1.6 1.0 0.6 −0.2
Accruals ratio — −4.5% −45.8% −13.3% −11.2% −9.2% −11.3% −9.8%

Source: SEC EDGAR XBRL filings (CIK 0001809519). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open